A wave of new drugs have revolutionised the weight loss industry. Now, getting your hands on one popular medication could get ...

SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Novo Nordisk said that it will begin offering its popular weight loss drug Wegovy through telehealth companies Hims & Hers, Ro and LifeMD to expand patient access, now that the medication is no longer ...

Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.